行情

NUVA

NUVA

纽瓦索器材
NASDAQ

实时行情|Nasdaq Last Sale

47.28
+0.38
+0.81%
盘后: 47.22 -0.06 -0.12% 16:00 12/03 EST
开盘
46.96
昨收
46.90
最高
47.73
最低
46.38
成交量
52.34万
成交额
--
52周最高
81.91
52周最低
28.55
市值
24.25亿
市盈率(TTM)
-217.1796
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
NuVasive Unveils C360 Portfolio, Launches New Anterior Cervical Plate
NuVasive Unveils C360 Portfolio and Launches New Anterior Cervical Plate SAN DIEGO, Nov. 30, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on
Benzinga · 3天前
NuVasive Announces Commercial Launch Of Cohere XLIF Interbody
SAN DIEGO, Nov. 18, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated
Benzinga · 11/18 13:35
NuVasive Q3 EPS $0.55 Beats $0.23 Estimate, Sales $295.30M Beat $256.11M Estimate
NuVasive (NASDAQ:NUVA) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.23 by 139.13 percent. This is a 6.78 percent decrease over earnings of $0.59 per share from the same
Benzinga · 10/29 20:24
The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 28)
Benzinga · 10/29 11:30
The Week Ahead In Biotech: Kala FDA Decision, Merck & Pfizer Earnings, Vaccine Updates And IPOs
Biotech stocks posted weekly declines in the week ended Oct. 23, pressured by the broader market decline amid mixed earnings reports and the impasse on fiscal stimulus.
Benzinga · 10/25 18:42
Benzinga's Top Upgrades, Downgrades For October 20, 2020
Upgrades * According to BMO Capital, the prior rating for Dave & Buster's Entertainment Inc (NASDAQ: PLAY) was changed from Market Perform to Outperform. In the second quarter, Dave & Buster's Enter showed an EPS of $1.24, compared to $0.90 from the year-ago quarter. At the moment, the stock has a 52-week-high of 48.8 and a 52-week-low of 4.605. Dave & Buster's Enter closed at $17.36 at the end of the last trading period. * According to Goldman Sachs, the prior rating for OGE Energy Corp (NYSE: OGE) was changed from Sell to Neutral. OGE Energy earned $0.51 in the second quarter, compared to $0.50 in the year-ago quarter. The current stock performance of OGE Energy shows a 52-week-high of 46.43 and a 52-week-low of 23.005. Moreover, at the end of the last trading period, the closing price was at $31.55. * According to Vertical Research, the prior rating for Lennox International Inc (NYSE: LII) was changed from Sell to Hold. Lennox International earned $3.53 in the third quarter, compared to $3.34 in the year-ago quarter. The stock has a 52-week-high of 297.0 and a 52-week-low of 163.395. At the end of the last trading period, Lennox International closed at $278.49. * For Fortinet Inc (NASDAQ: FTNT), Goldman Sachs upgraded the previous rating of Neutral to the current rating Buy. Fortinet earned $0.82 in the second quarter, compared to $0.58 in the year-ago quarter. The current stock performance of Fortinet shows a 52-week-high of 151.95 and a 52-week-low of 70.2. Moreover, at the end of the last trading period, the closing price was at $128.82. * Jefferies upgraded the previous rating for National Beverage Corp (NASDAQ: FIZZ) from Underperform to Hold. For the first quarter, National Beverage had an EPS of $1.09, compared to year-ago quarter EPS of $0.74. The stock has a 52-week-high of 86.265 and a 52-week-low of 35.71. At the end of the last trading period, National Beverage closed at $84.48. * RBC Capital upgraded the previous rating for Rayonier Advanced Materials Inc (NYSE: RYAM) from Sector Perform to Outperform. For the second quarter, Rayonier Advanced had an EPS of $0.20, compared to year-ago quarter EPS of $0.35. At the moment, the stock has a 52-week-high of 4.87 and a 52-week-low of 0.9001. Rayonier Advanced closed at $4.09 at the end of the last trading period. * JP Morgan upgraded the previous rating for Brunswick Corp (NYSE: BC) from Neutral to Overweight. In the second quarter, Brunswick showed an EPS of $0.99, compared to $1.45 from the year-ago quarter. The current stock performance of Brunswick shows a 52-week-high of 73.99 and a 52-week-low of 25.22. Moreover, at the end of the last trading period, the closing price was at $62.65. * According to Piper Sandler, the prior rating for Workday Inc (NASDAQ: WDAY) was changed from Neutral to Overweight. Workday earned $0.84 in the second quarter, compared to $0.44 in the year-ago quarter. At the moment, the stock has a 52-week-high of 248.75 and a 52-week-low of 107.75. Workday closed at $227.64 at the end of the last trading period. Downgrades * MKM Partners downgraded the previous rating for Concho Resources Inc (NYSE: CXO) from Buy to Neutral. Concho Resources earned $1.13 in the second quarter, compared to $0.69 in the year-ago quarter. At the moment, the stock has a 52-week-high of 93.34 and a 52-week-low of 33.13. Concho Resources closed at $47.27 at the end of the last trading period. * HC Wainwright & Co. downgraded the previous rating for BioSpecifics Technologies Corp (NASDAQ: BSTC) from Buy to Neutral. BioSpecifics Technologies earned $0.11 in the second quarter, compared to $0.87 in the year-ago quarter. At the moment, the stock has a 52-week-high of 88.69 and a 52-week-low of 42.0. BioSpecifics Technologies closed at $88.69 at the end of the last trading period. * Credit Suisse downgraded the previous rating for Front Yard Residential Corp (NYSE: RESI) from Outperform to Neutral. For the second quarter, Front Yard Residential had an EPS of $0.07, compared to year-ago quarter EPS of $0.47. The stock has a 52-week-high of 13.6899 and a 52-week-low of 6.01. At the end of the last trading period, Front Yard Residential closed at $13.36. * According to Goldman Sachs, the prior rating for Consolidated Edison Inc (NYSE: ED) was changed from Neutral to Sell. In the second quarter, Consolidated Edison showed an EPS of $0.60, compared to $0.58 from the year-ago quarter. The stock has a 52-week-high of 95.1 and a 52-week-low of 62.03. At the end of the last trading period, Consolidated Edison closed at $80.79. * According to National Bank Financial, the prior rating for Boyd Gaming Corp (NYSE: BYD) was changed from Outperform to Sector Perform. Boyd Gaming earned $0.98 in the second quarter, compared to $0.46 in the year-ago quarter. At the moment, the stock has a 52-week-high of 36.22 and a 52-week-low of 6.44. Boyd Gaming closed at $34.32 at the end of the last trading period. * For WPX Energy Inc (NYSE: WPX), KeyBanc downgraded the previous rating of Overweight to the current rating Sector Weight. For the second quarter, WPX Energy had an EPS of $0.12, compared to year-ago quarter EPS of $0.09. At the moment, the stock has a 52-week-high of 14.425 and a 52-week-low of 1.94. WPX Energy closed at $4.52 at the end of the last trading period. Initiations * SVB Leerink initiated coverage on Twist Bioscience Corp (NASDAQ: TWST) with a Market Perform rating. The price target for Twist Bioscience is set to $90.00. For the third quarter, Twist Bioscience had an EPS of $0.67, compared to year-ago quarter EPS of $0.92. The current stock performance of Twist Bioscience shows a 52-week-high of 100.3 and a 52-week-low of 18.52. Moreover, at the end of the last trading period, the closing price was at $93.00. * For Venus Concept Inc (NASDAQ: VERO), Ladenburg Thalmann initiated coverage, by setting the current rating at Buy. Interestingly, in the second quarter, Venus Concept's EPS was $0.39. The current stock performance of Venus Concept shows a 52-week-high of 9.0 and a 52-week-low of 2.02. Moreover, at the end of the last trading period, the closing price was at $2.59. * With a current rating of Buy, B of A Securities initiated coverage on Prelude Therapeutics Inc (NASDAQ: PRLD). The price target seems to have been set at $40.00 for Prelude Therapeutics. The current stock performance of Prelude Therapeutics shows a 52-week-high of 50.19 and a 52-week-low of 23.6931. Moreover, at the end of the last trading period, the closing price was at $32.69. * With a current rating of Buy, B of A Securities initiated coverage on PMV Pharmaceuticals Inc (NASDAQ: PMVP). The price target seems to have been set at $42.00 for PMV Pharmaceuticals. At the moment, the stock has a 52-week-high of 42.9316 and a 52-week-low of 31.5. PMV Pharmaceuticals closed at $37.46 at the end of the last trading period. * B of A Securities initiated coverage on Omeros Corp (NASDAQ: OMER) with a Buy rating. The price target for Omeros is set to $21.00. Omeros earned $0.61 in the second quarter, compared to $0.29 in the year-ago quarter. At the moment, the stock has a 52-week-high of 25.46 and a 52-week-low of 8.5. Omeros closed at $11.08 at the end of the last trading period. * With a current rating of Outperform, Cowen & Co. initiated coverage on Chart Industries Inc (NASDAQ: GTLS). The price target seems to have been set at $92.00 for Chart Industries. In the second quarter, Chart Industries showed an EPS of $0.63, compared to $0.68 from the year-ago quarter. The current stock performance of Chart Industries shows a 52-week-high of 85.895 and a 52-week-low of 15.0. Moreover, at the end of the last trading period, the closing price was at $83.10. * With a current rating of Outperform, SVB Leerink initiated coverage on Graybug Vision Inc (NASDAQ: GRAY). The price target seems to have been set at $35.00 for Graybug Vision. The stock has a 52-week-high of 20.74 and a 52-week-low of 12.5. At the end of the last trading period, Graybug Vision closed at $15.90. * Wolfe Research initiated coverage on Verizon Communications Inc (NYSE: VZ) with a Peer Perform rating. The price target for Verizon Communications is set to $62.00. Verizon Communications earned $1.18 in the second quarter, compared to $1.23 in the year-ago quarter. The current stock performance of Verizon Communications shows a 52-week-high of 62.22 and a 52-week-low of 48.84. Moreover, at the end of the last trading period, the closing price was at $57.31. * Wolfe Research initiated coverage on AT&T Inc (NYSE: T) with a Peer Perform rating. The price target for AT&T is set to $31.00. AT&T earned $0.83 in the second quarter, compared to $0.89 in the year-ago quarter. The current stock performance of AT&T shows a 52-week-high of 39.7 and a 52-week-low of 26.08. Moreover, at the end of the last trading period, the closing price was at $26.89. * With a current rating of Outperform, Oppenheimer initiated coverage on Pinduoduo Inc (NASDAQ: PDD). The price target seems to have been set at $100.00 for Pinduoduo. In the second quarter, Pinduoduo showed an EPS of $0.01, compared to $0.04 from the year-ago quarter. At the moment, the stock has a 52-week-high of 98.96 and a 52-week-low of 30.2. Pinduoduo closed at $84.15 at the end of the last trading period. * With a current rating of Buy, Stifel initiated coverage on NuVasive Inc (NASDAQ: NUVA). The price target seems to have been set at $64.00 for NuVasive. NuVasive earned $0.40 in the second quarter, compared to $0.63 in the year-ago quarter. The stock has a 52-week-high of 81.91 and a 52-week-low of 28.55. At the end of the last trading period, NuVasive closed at $52.40. * Piper Sandler initiated coverage on Graybug Vision Inc (NASDAQ: GRAY) with an Overweight rating. The price target for Graybug Vision is set to $27.00. The stock has a 52-week-high of 20.74 and a 52-week-low of 12.5. At the end of the last trading period, Graybug Vision closed at $15.90. * Stifel initiated coverage on Globus Medical Inc (NYSE: GMED) with a Hold rating. The price target for Globus Medical is set to $56.00. Globus Medical earned $0.07 in the second quarter, compared to $0.41 in the year-ago quarter. The stock has a 52-week-high of 60.15 and a 52-week-low of 33.41. At the end of the last trading period, Globus Medical closed at $54.79. * Mizuho initiated coverage on bluebird bio Inc (NASDAQ: BLUE) with a Buy rating. The price target for bluebird bio is set to $123.00. In the second quarter, bluebird bio showed an EPS of $0.36, compared to $3.55 from the year-ago quarter. The stock has a 52-week-high of 99.36 and a 52-week-low of 38.95. At the end of the last trading period, bluebird bio closed at $54.55. * Stifel initiated coverage on Alphatec Holdings Inc (NASDAQ: ATEC) with a Buy rating. The price target for Alphatec Holdings is set to $13.00. Alphatec Holdings earned $0.25 in the second quarter, compared to $0.26 in the year-ago quarter. At the moment, the stock has a 52-week-high of 11.38 and a 52-week-low of 2.19. Alphatec Holdings closed at $9.88 at the end of the last trading period. * With a current rating of Outperform, Baird initiated coverage on Amphenol Corp (NYSE: APH). The price target seems to have been set at $127.00 for Amphenol. Amphenol earned $0.81 in the second quarter, compared to $0.92 in the year-ago quarter. At the moment, the stock has a 52-week-high of 116.1 and a 52-week-low of 63.05. Amphenol closed at $112.99 at the end of the last trading period. * Compass Point initiated coverage on Mr. Cooper Group Inc (NASDAQ: COOP) with a Buy rating. The price target for Mr. Cooper Group is set to $30.00. In the second quarter, Mr. Cooper Group showed an EPS of $0.77, compared to $0.63 from the year-ago quarter. The current stock performance of Mr. Cooper Group shows a 52-week-high of 24.705 and a 52-week-low of 4.31. Moreover, at the end of the last trading period, the closing price was at $23.73. * With a current rating of Buy, Berenberg initiated coverage on VIA optronics AG (NYSE: VIAO). The price target seems to have been set at $22.00 for VIA optronics. At the moment, the stock has a 52-week-high of 12.4399 and a 52-week-low of 7.04. VIA optronics closed at $7.93 at the end of the last trading period.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Return On Capital Employed Overview: Cara Therapeutics * Return On Capital Employed Overview: Travelers Companies(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 10/20 14:56
NuVasive Q2 EPS $(0.40) Beats $(0.52) Estimate, Sales $203.60M Down From $292.11M YoY
NuVasive (NASDAQ:NUVA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.52) by 23.08 percent. This is a 163.49 percent decrease over earnings of $0.63 per share from the
Benzinga · 08/04 20:32
NuVasive Launches 'Time to Evolve' Campaign
Company launches Time to Evolve campaign to equip surgeons and hospital systems with tools and resources to support their evolution to less invasive surgical techniques   SAN DIEGO, July 22, 2020 /PRNewswire/
Benzinga · 07/22 12:34
更多
财务预测
每股收益每股净资产每股现金流
实际值(美元)
预测值(美元)
利润表更多
净利润营业总收入营业利润
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流(美元)
同比(%)
了解NUVA最新的财务预测,通过NUVA每股收益,每股净资产,每股现金流等数据分析纽瓦索器材近期的经营情况,然后做出明智的投资选择。
分析师评级

19位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测NUVA价格均价为61.88,最高价位76.00,最低价为48.00。
EPS
机构持股
总机构数: 447
机构持股: 5,812.89万
持股比例: 113.35%
总股本: 5,128.36万
类型机构数股数
增持
85
382.76万
建仓
73
-167.42万
减持
100
443.55万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
医疗设备、用品及经销
-1.85%
医疗设备和用品
-1.15%
高管信息
Chairman/Director
Gregory Lucier
Chief Executive Officer/Director
J. Christopher Barry
Chief Financial Officer/Executive Vice President
Matthew Harbaugh
Chief Human Resource Officer
Lucas Vitale
Executive Vice President
Brent Boucher
Executive Vice President
Massimo Calafiore
Senior Vice President/General Counsel/Secretary
Nathaniel Sisitsky
Senior Vice President
Dale Wolf
Independent Director
Vickie Capps
Independent Director
John DeFord
Independent Director
Robert Friel
Independent Director
R. Scott Huennekens
Independent Director
Leslie Norwalk
Independent Director
Donald Rosenberg
Independent Director
Daniel Wolterman
  • 分红
  • 拆股
  • 内部人交易
暂无数据
注册即可获得3个月
免费美股Level2深度行情
(Nasdaq Totalview)
立即领取
NUVA 简况
Nuvasive, Inc.是一家生产用于治疗脊椎疾病的医疗设备的公司。该公司专注于开发用于治疗脊椎疾病的微创破坏性手术产品及综合治疗解决方案。该公司提供两大类产品:脊柱外科产品以及生物制剂。脊柱外科产品包括胸腰椎治疗产品、颈椎治疗产品、术中监护服务产品及一次性用品。这些产品帮助医生通过微创破坏性手术完成患者脊椎的修复及融合。生物制剂产品包括同种异体移植物(捐赠的人体组织)、FormaGraft(胶原合成产品)、Osteocel Plus及Osteocel Pro(含有活性间充质干细胞的同种异体移植物细胞基质)以及AttraX(合成骨移植材料)。这些生物制剂产品用于辅助脊柱融合术及促进骨愈合。
展开
热门股票
代码
价格
涨跌幅

微牛提供NuVasive, Inc.(NASDAQ-NUVA)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的NUVA股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易NUVA股票基本功能。